This Study Collects Information on the Safety of Inhaled Pegylated Adrenomedullin (PEG-ADM), How the Drug is Tolerated and How it Affects Patients Suffering From a Type of Lung Failure That Cause Fluid to Build up in the Lungs Making Breathing Difficult (ARDS)

PHASE2TerminatedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

July 7, 2020

Primary Completion Date

December 28, 2022

Study Completion Date

December 28, 2022

Conditions
Acute Respiratory Distress Syndrome
Interventions
DRUG

BAY1097761 Active Dose 1

Participants will receive a lower dose ADM by inhalation

OTHER

Placebo to BAY1097761

Participants will receive Placebo to BAY1097761 by inhalation

DRUG

BAY1097761 Active Dose 2

Participants will receive a higher dose ADM by inhalation

Trial Locations (22)

1090

Universitätsklinikum AKH Wien, Vienna

6020

Medizinische Universität Innsbruck, Innsbruck

10034

Fakultni nemocnice Kralovske Vinohrady, Prague

13915

Hôpital du Nord - Marseille, Marseille

20089

Istituto Clinico Humanitas - Humanitas Mirasole S.p.A., Milan

20122

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan

20142

ASST Santi Paolo e Carlo, Milan

24105

Universitätsklinikum Schleswig-Holstein (UKSH), Kiel

26133

Klinikum Oldenburg AöR, Oldenburg

38700

Center Hospitalier Michallon - Grenoble, La Tronche

49933

Centre Hospitalier Universitaire - Angers, Angers

51109

Klinikum der Stadt Köln gGmbH - Krankenhaus Merheim, Cologne

67091

Hôpital Civil - Strasbourg, Strasbourg

75013

Hôpital de la Pitié-Salpétrière, Paris

75014

Cochin - Paris, Paris

150 06

Fakultni nemocnice v Motole, Prague

401 13

Masaryk Hospital Usti n/L, Ústí nad Labem

08208

Corporació Sanitària Parc Taulí, Sabadell

08035

Ciutat Sanitaria i Universitaria de la Vall d'Hebron, Barcelona

08041

Hospital de la Santa Creu i de Sant Pau, Barcelona

CF14 4XW

University Hospital of Wales, Cardiff

SE1 9RT

Guy's Hospital, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Bayer

INDUSTRY